ArticleCureus2026
Effectiveness of Medical Management in Heavy Menstrual Bleeding: A Prospective Cohort Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHeavy menstrual bleeding (HMB) is a prevalent gynecological condition among women in the reproductive and perimenopausal age groups, significantly impairing quality of life. While several medical treatment options are available, their comparative effectiveness and patient adherence vary. This study aimed to evaluate the effectiveness of medical management in HMB.
methodsThis prospective cohort study was carried out at a tertiary care institute in Central India from February 2023 to July 2024. The study included 240 women between 13 and 50 years of age presenting with HMB who opted for medical management. HMB was defined by a Pictorial Blood Loss Assessment Chart (PBAC) score of > 100. Women with HMB secondary to pregnancy complications, women needing surgical management, and women with postmenopausal bleeding were excluded from the study. Medical management was selected based on patient preference and clinical suitability. Outcome parameters like change in PBAC score and hemoglobin level were noted at baseline and reassessed at three and six months.
resultsThe mean age of participants was 41.03 ± 7.23 years. Baseline median PBAC scores (IQR) were: levonorgestrel intrauterine system (LNG-IUS) 475 (360-690), tranexamic acid 400 (255-600), norethisterone 645 (350-775), injectable depot medroxyprogesterone acetate (inj DMPA) 690 (355-956), and combined oral contraceptive pills (COCP) 380 (259-580). All five groups showed a significant reduction in PBAC scores at three and six months (p < 0.001). The greatest reduction at three months was seen with inj DMPA (78%), while LNG-IUS showed the highest reduction at six months (93%). A statistically significant improvement in hemoglobin levels was also observed over six months in all groups.
conclusionMedical management of HMB was effective in reducing menstrual blood loss and improving hemoglobin levels. LNG-IUS offered the most significant benefit with high compliance, but treatment choice should be individualized based on patient needs and clinical profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.